Glenmark Pharmaceuticals Limited

rs,

051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001 Scrip Name: GLENMARK ISIN: INE935A01035 Our Reference No. 17/26-

Rs. 37,706 million

produce without permission. 2 Summary – Q4 FY26 Consolidated Revenue • Consolidated Revenue of Rs. 37,706 million • YoY growth of 15.8% Regional Highlights India business growth of 8.2% • • North America core

15.8%

ary – Q4 FY26 Consolidated Revenue • Consolidated Revenue of Rs. 37,706 million • YoY growth of 15.8% Regional Highlights India business growth of 8.2% • • North America core business growth of 7.8

8.2%

evenue of Rs. 37,706 million • YoY growth of 15.8% Regional Highlights India business growth of 8.2% • • North America core business growth of 7.8% • EU business growth of 21.4% • EM business growth

7.8%

.8% Regional Highlights India business growth of 8.2% • • North America core business growth of 7.8% • EU business growth of 21.4% • EM business growth of 13.7% Profitability • EBITDA at Rs. 7,626 m

21.4%

dia business growth of 8.2% • • North America core business growth of 7.8% • EU business growth of 21.4% • EM business growth of 13.7% Profitability • EBITDA at Rs. 7,626 million • EBITDA margin of 20.

13.7%

• North America core business growth of 7.8% • EU business growth of 21.4% • EM business growth of 13.7% Profitability • EBITDA at Rs. 7,626 million • EBITDA margin of 20.2% • PAT at Rs. 3,013 million

Rs. 7,626 million

wth of 7.8% • EU business growth of 21.4% • EM business growth of 13.7% Profitability • EBITDA at Rs. 7,626 million • EBITDA margin of 20.2% • PAT at Rs. 3,013 million with PAT margin of 7.6% “FY26 has been a defi

20.2%

.4% • EM business growth of 13.7% Profitability • EBITDA at Rs. 7,626 million • EBITDA margin of 20.2% • PAT at Rs. 3,013 million with PAT margin of 7.6% “FY26 has been a defining year in Glenmark’s ev

Rs. 3,013 million

ss growth of 13.7% Profitability • EBITDA at Rs. 7,626 million • EBITDA margin of 20.2% • PAT at Rs. 3,013 million with PAT margin of 7.6% “FY26 has been a defining year in Glenmark’s evolution. We delivered str

7.6%

EBITDA at Rs. 7,626 million • EBITDA margin of 20.2% • PAT at Rs. 3,013 million with PAT margin of 7.6% “FY26 has been a defining year in Glenmark’s evolution. We delivered strong business performance

700 million

. 3 Key Highlights – FY26 IGI secured a landmark licensing deal with AbbVie for ISB 2001 USD 700 million upfront payment with potential total deal value of USD 1.925 billion, tiered double- digit royalt